Skip to main content
. 2021 Jun 22;10(7):1568. doi: 10.3390/cells10071568

Figure 1.

Figure 1

Predictive model of the immunotherapy efficacy in young and old patients. In old patients, we expected a loss of immunotherapy efficacy. Within the TME, the decrease in immune cell fitness with the enrichment of senescent cells and immunosuppressive cells (MDSC, Tregs, and CAFs) can be responsible for this resistance. Pretreatment with a senolytic drug could reverse this immunosuppressive context and enhance the immunotherapy efficacy in aged patients.